A Phase 2 Study of XmAb 20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer
Brief description of study
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of XmAb20717 in patients with selected advanced gynecologic and genitourinary malignancies.
Clinical Study Identifier: s22-00496
ClinicalTrials.gov Identifier: NCT05032040
Principal Investigator:
David R. Wise.
Other Investigators:
Kathleen M Lutz,
Fabia Brisard Pierrot,
Christina Grace Wilson,
Marina Stasenko,
Kent Chan,
Michelle Diane Swanson Lightfoot,
Emeline Mariam Aviki,
Minas Platon Economides,
Edward A Jimenez,
Erin Annette Reese,
Bhavana Pothuri,
Scot Niglio,
Victor Ricardo Adorno Febles,
Whitfield B. Growdon,
Deanna Gerber,
Caitlin Elizabeth Ryan,
Kelly A Levine,
Olivia Richardson Khouri,
Hank Ng,
Alexander A Hindenburg.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.